News stories about CTD (OTCMKTS:CTDH) have trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CTD earned a coverage optimism score of 1.14 on their scale. InfoTrie also gave headlines about the biotechnology company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the next few days.
Shares of OTCMKTS CTDH opened at $0.80 on Friday. CTD has a fifty-two week low of $0.25 and a fifty-two week high of $0.95.
CTD Company Profile
CTD Holdings, Inc, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Neimann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Receive News & Ratings for CTD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTD and related companies with MarketBeat.com's FREE daily email newsletter.